Cited 28 times in

Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial

DC Field Value Language
dc.contributor.author김형일-
dc.contributor.author노성훈-
dc.contributor.author손태일-
dc.contributor.author정재호-
dc.contributor.author조민아-
dc.contributor.author최서희-
dc.contributor.author최윤영-
dc.contributor.author허용민-
dc.contributor.author형우진-
dc.date.accessioned2019-07-23T06:41:00Z-
dc.date.available2019-07-23T06:41:00Z-
dc.date.issued2019-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170271-
dc.description.abstractClinical implications of single patient classifier (SPC) and microsatellite instability (MSI) in stage II/III gastric cancer have been reported. We investigated SPC and the status of MSI and Epstein-Barr virus (EBV) as combinatory biomarkers to predict the prognosis and responsiveness of adjuvant chemotherapy for stage II/III gastric cancer. MATERIALS AND METHODS: Tumor specimens and clinical information were collected from patients enrolled in CLASSIC trial, a randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. The results of nine-gene based SPC assay were classified as prognostication (SPC-prognosis) and prediction of chemotherapy benefit (SPC-prediction). Five quasimonomorphic mononucleotide markers were used to assess tumor MSI status. EBV-encoded small RNA in situ hybridization was performed to define EBV status. RESULTS: There were positive associations among SPC, MSI, and EBV statuses among 586 patients. In multivariate analysis of disease-free survival, SPC-prognosis [hazard ratio (HR): 1.879 (1.101-3.205), 2.399 (1.415-4.067), p=0.003] and MSI status (HR: 0.363, 95% confidence interval: 0.161-0.820, p=0.015) were independent prognostic factors along with age, Lauren classification, TNM stage, and chemotherapy. Patient survival of SPC-prognosis was well stratified regardless of EBV status and in microsatellite stable (MSS) group, but not in MSI-high group. Significant survival benefit from adjuvant chemotherapy was observed by SPC-Prediction in MSS and EBV-negative gastric cancer. CONCLUSION: SPC, MSI, and EBV statuses could be used in combination to predict the prognosis and responsiveness of adjuvant chemotherapy for stage II/III gastric cancer. © Copyright: Yonsei University College of Medicine 2019.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleSingle Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorChul Kyu Roh-
dc.contributor.googleauthorYoon Young Choi-
dc.contributor.googleauthorSeohee Choi-
dc.contributor.googleauthorWon Jun Seo-
dc.contributor.googleauthorMinah Cho-
dc.contributor.googleauthorEunji Jang-
dc.contributor.googleauthorTaeil Son-
dc.contributor.googleauthorHyoung-Il Kim-
dc.contributor.googleauthorHyeseon Kim-
dc.contributor.googleauthorWoo Jin Hyung-
dc.contributor.googleauthorYong-Min Huh-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorJae-Ho Cheong-
dc.identifier.doi10.3349/ymj.2019.60.2.132-
dc.contributor.localIdA01154-
dc.contributor.localIdA01281-
dc.contributor.localIdA01998-
dc.contributor.localIdA03717-
dc.contributor.localIdA05418-
dc.contributor.localIdA05052-
dc.contributor.localIdA04138-
dc.contributor.localIdA04359-
dc.contributor.localIdA04382-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid30666834-
dc.subject.keywordEBV-
dc.subject.keywordGastriccancer-
dc.subject.keywordmicrosatelliteinstability-
dc.subject.keywordsinglepatientclassifier-
dc.contributor.alternativeNameKim, Hyoung Il-
dc.contributor.affiliatedAuthor김형일-
dc.contributor.affiliatedAuthor노성훈-
dc.contributor.affiliatedAuthor손태일-
dc.contributor.affiliatedAuthor정재호-
dc.contributor.affiliatedAuthor조민아-
dc.contributor.affiliatedAuthor최서희-
dc.contributor.affiliatedAuthor최윤영-
dc.contributor.affiliatedAuthor허용민-
dc.contributor.affiliatedAuthor형우진-
dc.citation.volume60-
dc.citation.number2-
dc.citation.startPage132-
dc.citation.endPage139-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.60(2) : 132-139, 2019-
dc.identifier.rimsid62770-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.